Viewing Study NCT04758650



Ignite Creation Date: 2024-05-06 @ 3:46 PM
Last Modification Date: 2024-10-26 @ 1:57 PM
Study NCT ID: NCT04758650
Status: RECRUITING
Last Update Posted: 2023-11-18
First Post: 2021-02-12

Brief Title: Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions Cardiovascular Atherosclerosis Syndrome With Abnormal Immune Activation and sarcoïdosis
Sponsor: Universitair Ziekenhuis Brussel
Organization: Universitair Ziekenhuis Brussel

Study Overview

Official Title: Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography PET in Oncological LesionsCardiovascular AtherosclerosisSyndrome With Abnormal Immune Activation and sarcoïdosis
Status: RECRUITING
Status Verified Date: 2023-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: MITRAS
Brief Summary: Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor MMR-expressing Macrophages by means of Positron Emission Tomography PET in patients with oncological lesions in need of non-surgical therapy patients with cardiovascular atherosclerosis syndrome with abnormal immune activation and sarcoïdosis
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
2020-002483-31 EUDRACT_NUMBER None None